Leonard Calabrese

2 weeks ago | healio.com | Leonard Calabrese |Jason Laday

In this Healio video exclusive, Leonard H. Calabrese, DO, chief medical editor of Healio Rheumatology, highlighted recent coverage of the rise in physician union membership, as well as Congress’s latest stopgap funding measure. “It’s really quite varied and it’s really on some of the business, funding, intellectual aspects of our profession,” Calabrese said. “Unionization — plusses and minuses.

4 weeks ago | healio.com | Leonard Calabrese |Shenaz Bagha

I’m thrilled to share my reflections on the book Masterclass in Medicine: Lessons from the Experts, along with highlights from our insightful discussion with one of the editors, Jason Liebowitz, MD, about its goals and intent. I just finished reading the book and I can’t stop thinking about why it moved me so deeply. After all, the field of medicine is filled with publications covering every facet of our craft, from basic and clinical science to medical humanism and beyond.

1 month ago | healio.com | Leonard Calabrese |Shenaz Bagha

This month, our featured roundtable explores the evolution and progress of a rapidly emerging interdisciplinary clinical model — the cardio-rheumatology clinic. In these collaborative settings, rheumatologists, cardiologists and other cardiovascular specialists work together to deliver integrated care, advance research and foster education. I would like to extend my heartfelt gratitude to our contributors — Luigi Adamo, MD; Joshua F. Baker, MD; Julie J.

1 month ago | healio.com | Rob Volansky |Shenaz Bagha |Leonard Calabrese

Last November, results from the MITIGATE trial made headlines at ACR Convergence 2024 with positive phase 3 trial data for inebilizumab, an IgG1 monoclonal antibody targeting CD19, in patients with IgG4-related disease. That trial, the first randomized, double-blind, placebo-controlled study ever conducted in IgG4-RD, confirmed “beyond doubt” that B-cell depletion is an effective treatment strategy for the disease, John H.

2 months ago | healio.com | Leonard Calabrese |Shenaz Bagha

The field of rheumatology is constantly in flux. As I look back over my career, I see periods of calm within individual disease areas where progress was slow, far from occurring within the blink of an eye. Rheumatoid arthritis in the 1980s and ‘90s moved very slow (think RA and NSAIDS pre-methotrexate), but with the introduction of biologics the study of RA, and especially its care, has been transformed into something previously unrecognizable.